Australian biotechnology innovator Beroni Group has become the first company to join the OTCQX Best Market from the National Stock Exchange of Australia, opening the medical health provider to the massive US investor market.
Beroni, which is investigating a range of cell therapies, anti-cancer drugs and disease solutions for commercialisation in China, Japan, Australia and the US, will trade on the OTCQX under the code “BNIGF”.
Commenting on the newly minted listing Beroni Group chairman and CEO, Jacky Zhang said, “Beroni Group is pleased to be traded on the OTCQX Market which will give us access to the U.S. capital market.
The OTCQX Market offers U.S.-based investors the opportunity to invest in Beroni Group and the exciting growth potential that the Company provides.
With trading on OTCQX, Beroni Group will be looking for business opportunities in the U.S. such as partnering with other biomedicine industry leaders by way of research joint ventures and clinical trials for potential new high growth biomedicine products.”
“It is also interested to join forces with U.S. biotechnology companies to develop the global biopharmaceutical business.”
The Group is well connected to the medical sciences communities in both the USA and Australia, with Boroni holding a sponsored research agreement with Columbia University, New York, to better detect the Zika virus, dengue virus and West Nile virus, among others.
Boroni is also developing an anti-cancer drug PENAO with the University of NSW, which is expected to commence Phase 2 clinical trials this year.
Jason Paltrowitz, executive vice president of Corporate Services at OTC Markets Group added:
“As the first company from the National Stock Exchange of Australia to begin trading on OTCQX, Beroni Group joins an impressive roster of international companies providing a transparent market for their U.S. investors.
“We look forward to supporting Beroni Group as the company builds visibility and long-term shareholder value in the U.S. public market.”
